Market Overview

UPDATE: Morgan Stanley Reiterates on AbbVie After Competitor's Schizophrenia Drug Fails

Share:
Related
Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price
The Market In 5 Minutes: Retail Earnings Come Into Focus
Biotech Forum Daily Digest: Biotech Has Tough Week; Will Conference Buoy Immunotherapy Concerns? (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on AbbVie (NYSE: ABBV), but removed the $57.00 price target.

In the report, Morgan Stanley noted, “Targacept's (not covered) cognitive deficits in schizophrenia (CDS) drug, TC-5619, failed. This drug is similar to ABBV's ABT-126, which is being tested in Ph. IIb in both cognition in Alzheimer's and CDS. We have been estimating 20% odds of ABBV success in one of the two indications.”

AbbVie closed on Monday at $53.37.

Latest Ratings for ABBV

DateFirmActionFromTo
Nov 2016CitigroupDowngradesBuyNeutral
Oct 2016Credit SuisseDowngradesOutperformNeutral
Oct 2016Leerink SwannInitiates Coverage OnMarket Perform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!